Literature DB >> 19608868

MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

Goleeta Alam1, Hongjuan Cui, Huilin Shi, Liqun Yang, Jane Ding, Ling Mao, William A Maltese, Han-Fei Ding.   

Abstract

Amplification of the oncogene MYCN is a tumorigenic event in the development of a subset of neuroblastomas that commonly consist of undifferentiated or poorly differentiated neuroblasts with unfavorable clinical outcome. The cellular origin of these neuroblasts is unknown. Additionally, the cellular functions and target cells of MYCN in neuroblastoma development remain undefined. Here we examine the cell types that drive neuroblastoma development in TH-MYCN transgenic mice, an animal model of the human disease. Neuroblastoma development in these mice begins with hyperplastic lesions in early postnatal sympathetic ganglia. We show that both hyperplasia and primary tumors are composed predominantly of highly proliferative Phox2B(+) neuronal progenitors. MYCN induces the expansion of these progenitors by both promoting their proliferation and preventing their differentiation. We further identify a minor population of undifferentiated nestin(+) cells in both hyperplastic lesions and primary tumors that may serve as precursors of Phox2B(+) neuronal progenitors. These findings establish the identity of neuroblasts that characterize the tumor phenotype and suggest a cellular pathway by which MYCN can promote neuroblastoma development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608868      PMCID: PMC2716980          DOI: 10.2353/ajpath.2009.090019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  Isolation of a stem cell for neurons and glia from the mammalian neural crest.

Authors:  D L Stemple; D J Anderson
Journal:  Cell       Date:  1992-12-11       Impact factor: 41.582

2.  Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop.

Authors:  B R Stanton; A S Perkins; L Tessarollo; D A Sassoon; L F Parada
Journal:  Genes Dev       Date:  1992-12       Impact factor: 11.361

3.  Ki67--structure, function, and new antibodies.

Authors:  N Sawhney; P A Hall
Journal:  J Pathol       Date:  1992-10       Impact factor: 7.996

4.  CNS stem cells express a new class of intermediate filament protein.

Authors:  U Lendahl; L B Zimmerman; R D McKay
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

Review 5.  Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate.

Authors:  C J Thiele; M A Israel
Journal:  Exp Cell Biol       Date:  1988

6.  Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group.

Authors:  V V Joshi; A B Cantor; G Altshuler; E W Larkin; J S Neill; J J Shuster; C T Holbrook; F A Hayes; R P Castleberry
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

7.  Mammalian achaete-scute homolog 1 is transiently expressed by spatially restricted subsets of early neuroepithelial and neural crest cells.

Authors:  L C Lo; J E Johnson; C W Wuenschell; T Saito; D J Anderson
Journal:  Genes Dev       Date:  1991-09       Impact factor: 11.361

8.  Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene.

Authors:  J Charron; B A Malynn; P Fisher; V Stewart; L Jeannotte; S P Goff; E J Robertson; F W Alt
Journal:  Genes Dev       Date:  1992-12       Impact factor: 11.361

9.  Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts.

Authors:  M J Cooper; G M Hutchins; P S Cohen; L J Helman; R J Mennie; M A Israel
Journal:  Cell Growth Differ       Date:  1990-04

10.  N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification.

Authors:  M Badiali; A Pession; G Basso; L Andreini; L Rigobello; E Galassi; F Giangaspero
Journal:  Tumori       Date:  1991-04-30
View more
  38 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

2.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Authors:  Shizhen Zhu; Jeong-Soo Lee; Feng Guo; Jimann Shin; Antonio R Perez-Atayde; Jeffery L Kutok; Scott J Rodig; Donna S Neuberg; Daniel Helman; Hui Feng; Rodney A Stewart; Wenchao Wang; Rani E George; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells.

Authors:  Takayuki Hirano; Eri Nagasaki-Maeoka; Yoshiaki Ishizuka; Atsushi Takatori; Yosuke Watanabe; Reina Hoshi; Shinsuke Yoshizawa; Hiroyuki Kawashima; Shota Uekusa; Kiminobu Sugito; Shuichiro Uehara; Noboru Fukuda; Hiroki Nagase; Tadateru Takayama; Masayoshi Soma; Tsugumichi Koshinaga; Kyoko Fujiwara
Journal:  Med Oncol       Date:  2019-06-10       Impact factor: 3.064

Review 4.  From proliferation to target innervation: signaling molecules that direct sympathetic nervous system development.

Authors:  W H Chan; C R Anderson; David G Gonsalvez
Journal:  Cell Tissue Res       Date:  2017-10-02       Impact factor: 5.249

5.  Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.

Authors:  Marco Kramer; Diogo Ribeiro; Marie Arsenian-Henriksson; Thomas Deller; Hermann Rohrer
Journal:  J Neurosci       Date:  2016-10-05       Impact factor: 6.167

6.  Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.

Authors:  Mengling Liu; Yingfeng Xia; Jane Ding; Bingwei Ye; Erhu Zhao; Jeong-Hyeon Choi; Ahmet Alptekin; Chunhong Yan; Zheng Dong; Shuang Huang; Liqun Yang; Hongjuan Cui; Yunhong Zha; Han-Fei Ding
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

7.  Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.

Authors:  Tal Teitz; Madoka Inoue; Marcus B Valentine; Kejin Zhu; Jerold E Rehg; Wei Zhao; David Finkelstein; Yong-Dong Wang; Melissa D Johnson; Christopher Calabrese; Marcelo Rubinstein; Razqallah Hakem; William A Weiss; Jill M Lahti
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

8.  PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.

Authors:  Tiziana Bachetti; Daniela Di Paolo; Simona Di Lascio; Valentina Mirisola; Chiara Brignole; Marta Bellotti; Irene Caffa; Chiara Ferraris; Michele Fiore; Diego Fornasari; Roberto Chiarle; Silvia Borghini; Ulrich Pfeffer; Mirco Ponzoni; Isabella Ceccherini; Patrizia Perri
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

9.  Ciliary neurotrophic factor reduces the proliferation and promotes the differentiation of TH- MYCN transformed sympathoadrenal progenitors.

Authors:  John DeWitt; Anthony Pappas; Rae Nishi
Journal:  Dev Neurosci       Date:  2014-08-20       Impact factor: 2.984

10.  Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Authors:  Daniel R Carter; Selina K Sutton; Marina Pajic; Jayne Murray; Eric O Sekyere; Jamie Fletcher; Anneleen Beckers; Katleen De Preter; Frank Speleman; Rani E George; Michelle Haber; Murray D Norris; Belamy B Cheung; Glenn M Marshall
Journal:  Mol Oncol       Date:  2016-03-02       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.